{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:19Z","timestamp":1792787959680,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82472868 and 82172585"],"award-info":[{"award-number":["82472868 and 82172585"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Guangzhou Municipal Institute Enterprise Joint Funding Project","award":["2024A03J0101"],"award-info":[{"award-number":["2024A03J0101"]}]},{"name":"the Science and Technology Program of Guangzhou","award":["202103000051"],"award-info":[{"award-number":["202103000051"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-024-02416-2","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T01:44:14Z","timestamp":1736473454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics"],"prefix":"10.1186","volume":"24","author":[{"given":"Jinliang","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoshou","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunhua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"issue":"9","key":"2416_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/s2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851\u201361. https:\/\/doi.org\/10.1016\/s2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10290","key":"2416_CR2","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/s0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(20)32511-3.","journal-title":"Lancet"},{"key":"2416_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jare.2023.01.008","volume":"52","author":"H-Y Li","year":"2023","unstructured":"Li H-Y, Huang S-Y, Zhou D-D, et al. Theabrownin inhibits obesity and non-alcoholic fatty liver disease in mice via serotonin-related signaling pathways and gut-liver axis. J Adv Res. 2023;52:59\u201372. https:\/\/doi.org\/10.1016\/j.jare.2023.01.008.","journal-title":"J Adv Res"},{"issue":"3","key":"2416_CR4","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Allen AM, Dubourg J, et al. Challenges and opportunities in NASH drug development. Nat Med. 2023;29(3):562\u201373. https:\/\/doi.org\/10.1038\/s41591-023-02242-6.","journal-title":"Nat Med"},{"issue":"1","key":"2416_CR5","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1038\/s41467-024-48956-0","volume":"15","author":"L Verschuren","year":"2024","unstructured":"Verschuren L, Mak AL, van Koppen A, et al. Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD. Nat Commun. 2024;15(1):4564. https:\/\/doi.org\/10.1038\/s41467-024-48956-0.","journal-title":"Nat Commun"},{"issue":"9","key":"2416_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691\u2013705. https:\/\/doi.org\/10.1136\/gutjnl-2020-320622.","journal-title":"Gut"},{"issue":"7","key":"2416_CR7","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/s2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach, the lancet. Gastroenterol Hepatol. 2021;6(7):578\u201388. https:\/\/doi.org\/10.1016\/s2468-1253(21)00020-0.","journal-title":"Gastroenterol Hepatol"},{"issue":"4","key":"2416_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","volume":"19","author":"R Hammoud","year":"2023","unstructured":"Hammoud R, Drucker. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1, Nature reviews. Endocrinology. 2023;19(4):201\u201316. https:\/\/doi.org\/10.1038\/s41574-022-00783-3.","journal-title":"Endocrinology"},{"issue":"1","key":"2416_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.21006","volume":"43","author":"X Ding","year":"2006","unstructured":"Ding X, Saxena NK, Lin S, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice. Hepatology (Baltimore MD). 2006;43(1):173\u201381. https:\/\/doi.org\/10.1002\/hep.21006.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"4","key":"2416_CR10","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like Peptide-1. Cell Metabol. 2018;27(4):740\u201356. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001.","journal-title":"Cell Metabol"},{"issue":"5","key":"2416_CR11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","volume":"30","author":"AE Adriaenssens","year":"2019","unstructured":"Adriaenssens AE, Biggs EK, Darwish T, et al. Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the Hypothalamus regulate Food Intake. Cell Metabol. 2019;30(5):987\u2013e996986. https:\/\/doi.org\/10.1016\/j.cmet.2019.07.013.","journal-title":"Cell Metabol"},{"issue":"4","key":"2416_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","volume":"33","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metabol. 2021;33(4):833\u2013e844835. https:\/\/doi.org\/10.1016\/j.cmet.2021.01.015.","journal-title":"Cell Metabol"},{"issue":"24","key":"2416_CR13","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber D, Barrett T, Barrientos-P\u00e9rez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2208601.","journal-title":"N Engl J Med"},{"issue":"11","key":"2416_CR14","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","volume":"82","author":"YY Syed","year":"2022","unstructured":"Syed YY. Tirzepatide: First Approval Drugs. 2022;82(11):1213\u201320. https:\/\/doi.org\/10.1007\/s40265-022-01746-8.","journal-title":"Tirzepatide: First Approval Drugs"},{"issue":"6","key":"2416_CR15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","volume":"31","author":"RJ Samms","year":"2020","unstructured":"Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends in endocrinology and metabolism. TEM. 2020;31(6):410\u201321. https:\/\/doi.org\/10.1016\/j.tem.2020.02.006.","journal-title":"TEM"},{"issue":"6","key":"2416_CR16","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s42255-023-00811-0","volume":"5","author":"K El","year":"2023","unstructured":"El K, Douros JD, Willard FS, et al. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nat Metabolism. 2023;5(6):945\u201354. https:\/\/doi.org\/10.1038\/s42255-023-00811-0.","journal-title":"Nat Metabolism"},{"key":"2416_CR17","doi-asserted-by":"publisher","unstructured":"Samms RJ, Christe ME, Collins KA, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Investig. 2021;131(12). https:\/\/doi.org\/10.1172\/jci146353.","DOI":"10.1172\/jci146353"},{"issue":"11","key":"2416_CR18","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909\u201318. https:\/\/doi.org\/10.1038\/s41591-023-02597-w.","journal-title":"Nat Med"},{"issue":"3","key":"2416_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once Weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"key":"2416_CR20","doi-asserted-by":"publisher","first-page":"1146960","DOI":"10.3389\/fphar.2023.1146960","volume":"14","author":"X Guo","year":"2023","unstructured":"Guo X, Lei M, Zhao J, et al. Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats. Front Pharmacol. 2023;14:1146960. https:\/\/doi.org\/10.3389\/fphar.2023.1146960.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2416_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/s2468-1253(22)00338-7","volume":"8","author":"G Targher","year":"2023","unstructured":"Targher G, Mantovani A, Byrne CD. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease, the lancet. Gastroenterol Hepatol. 2023;8(2):179\u201391. https:\/\/doi.org\/10.1016\/s2468-1253(22)00338-7.","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"2416_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","volume":"18","author":"Y Hasin","year":"2017","unstructured":"Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83. https:\/\/doi.org\/10.1186\/s13059-017-1215-1.","journal-title":"Genome Biol"},{"issue":"1","key":"2416_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12859-017-1579-y","volume":"18","author":"B Wen","year":"2017","unstructured":"Wen B, Mei Z, Zeng C, et al. metaX: a flexible and comprehensive software for processing metabolomics data. BMC Bioinformatics. 2017;18(1):183. https:\/\/doi.org\/10.1186\/s12859-017-1579-y.","journal-title":"BMC Bioinformatics"},{"issue":"13","key":"2416_CR24","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1021\/ac051632c","volume":"78","author":"F Dieterle","year":"2006","unstructured":"Dieterle F, Ross A, Schlotterbeck G, et al. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem. 2006;78(13):4281\u201390. https:\/\/doi.org\/10.1021\/ac051632c.","journal-title":"Anal Chem"},{"issue":"7","key":"2416_CR25","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/nprot.2011.335","volume":"6","author":"WB Dunn","year":"2011","unstructured":"Dunn WB, Broadhurst D, Begley P, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. 2011;6(7):1060\u201383. https:\/\/doi.org\/10.1038\/nprot.2011.335.","journal-title":"Nat Protoc"},{"issue":"6","key":"2416_CR26","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.cmet.2018.04.015","volume":"27","author":"PJ White","year":"2018","unstructured":"White PJ, McGarrah RW, Grimsrud PA, et al. The BCKDH kinase and Phosphatase Integrate BCAA and lipid metabolism via regulation of ATP-Citrate lyase. Cell Metabol. 2018;27(6):1281\u2013e12931287. https:\/\/doi.org\/10.1016\/j.cmet.2018.04.015.","journal-title":"Cell Metabol"},{"issue":"7721","key":"2416_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41586-018-0466-7","volume":"561","author":"G Eelen","year":"2018","unstructured":"Eelen G, Dubois C, Cantelmo AR, et al. Role of glutamine synthetase in angiogenesis beyond glutamine synthesis. Nature. 2018;561(7721):63\u20139. https:\/\/doi.org\/10.1038\/s41586-018-0466-7.","journal-title":"Nature"},{"key":"2416_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev.nutr.012809.104810","volume":"30","author":"AS Tibbetts","year":"2010","unstructured":"Tibbetts AS, Appling DR. Compartmentalization of mammalian folate-mediated one-carbon metabolism. Annu Rev Nutr. 2010;30:57\u201381. https:\/\/doi.org\/10.1146\/annurev.nutr.012809.104810.","journal-title":"Annu Rev Nutr"},{"issue":"12","key":"2416_CR29","doi-asserted-by":"publisher","first-page":"e13081","DOI":"10.1111\/obr.13081","volume":"21","author":"I Pregui\u00e7a","year":"2020","unstructured":"Pregui\u00e7a I, Alves A, Nunes S, et al. Diet-induced rodent models of obesity-related metabolic disorders-A guide to a translational perspective. Obes Reviews: Official J Int Association Study Obes. 2020;21(12):e13081. https:\/\/doi.org\/10.1111\/obr.13081.","journal-title":"Obes Reviews: Official J Int Association Study Obes"},{"key":"2416_CR30","doi-asserted-by":"publisher","unstructured":"Della Torre S. Beyond the X factor: relevance of sex hormones in NAFLD Pathophysiology. Cells. 2021;10(9). https:\/\/doi.org\/10.3390\/cells10092502.","DOI":"10.3390\/cells10092502"},{"issue":"5","key":"2416_CR31","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264\u2013e12811264. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.036.","journal-title":"Gastroenterology"},{"issue":"4","key":"2416_CR32","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73(4):691\u2013702. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595.","journal-title":"Gut"},{"issue":"5","key":"2416_CR33","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","volume":"70","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021;70(5):962\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2020-322572.","journal-title":"Gut"},{"issue":"7","key":"2416_CR34","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908\u201322. https:\/\/doi.org\/10.1038\/s41591-018-0104-9.","journal-title":"Nat Med"},{"issue":"6","key":"2416_CR35","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/s2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2\u00b74\u00a0mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial, the lancet. Gastroenterol Hepatol. 2023;8(6):511\u201322. https:\/\/doi.org\/10.1016\/s2468-1253(23)00068-7.","journal-title":"Gastroenterol Hepatol"},{"key":"2416_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.034","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Rolph T, Knot M, et al. FGF21 agonists: an emerging therapeutic for metabolic dysfunction-Associated Steatohepatitis and Beyond. J Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.034.","journal-title":"J Hepatol"},{"issue":"10295","key":"2416_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/s0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (London England). 2021;398(10295):143\u201355. https:\/\/doi.org\/10.1016\/s0140-6736(21)01324-6.","journal-title":"Lancet (London England)"},{"key":"2416_CR38","doi-asserted-by":"publisher","first-page":"104684","DOI":"10.1016\/j.ebiom.2023.104684","volume":"93","author":"Z Ying","year":"2023","unstructured":"Ying Z, van Eenige R, Ge X, et al. Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE\u22173-Leiden.CETP mice. EBioMedicine. 2023;93:104684. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104684.","journal-title":"EBioMedicine"},{"issue":"10","key":"2416_CR39","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1172\/jci75276","volume":"124","author":"A Secher","year":"2014","unstructured":"Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Investig. 2014;124(10):4473\u201388. https:\/\/doi.org\/10.1172\/jci75276.","journal-title":"J Clin Investig"},{"key":"2416_CR40","doi-asserted-by":"publisher","unstructured":"Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6). https:\/\/doi.org\/10.1172\/jci.insight.133429.","DOI":"10.1172\/jci.insight.133429"},{"issue":"2","key":"2416_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s13340-017-0317-z","volume":"8","author":"N Harada","year":"2017","unstructured":"Harada N, Inagaki N. Role of GIP receptor signaling in \u03b2-cell survival. Diabetol Int. 2017;8(2):137\u20138. https:\/\/doi.org\/10.1007\/s13340-017-0317-z.","journal-title":"Diabetol Int"},{"key":"2416_CR42","doi-asserted-by":"publisher","unstructured":"Frias JP, Bastyr EJ 3rd, Vignati L, et al. The Sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metabol. 2017;26(2):343\u2013e352342. https:\/\/doi.org\/10.1016\/j.cmet.2017.07.011.","DOI":"10.1016\/j.cmet.2017.07.011"},{"key":"2416_CR43","doi-asserted-by":"publisher","unstructured":"Liu Z, Liu M, Fan M, et al. Metabolomic-proteomic combination analysis reveals the targets and molecular pathways associated with hydrogen sulfide alleviating NAFLD. Life Sci. 2021;264:118629. https:\/\/doi.org\/10.1016\/j.lfs.2020.118629.","DOI":"10.1016\/j.lfs.2020.118629"},{"issue":"3","key":"2416_CR44","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jhep.2018.04.006","volume":"69","author":"L Zhao","year":"2018","unstructured":"Zhao L, Zhang C, Luo X, et al. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis. J Hepatol. 2018;69(3):705\u201317. https:\/\/doi.org\/10.1016\/j.jhep.2018.04.006.","journal-title":"J Hepatol"},{"issue":"1","key":"2416_CR45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1055\/s-2001-12928","volume":"21","author":"MS Rao","year":"2001","unstructured":"Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis. 2001;21(1):43\u201355. https:\/\/doi.org\/10.1055\/s-2001-12928.","journal-title":"Semin Liver Dis"},{"issue":"18","key":"2416_CR46","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","volume":"75","author":"DH Ipsen","year":"2018","unstructured":"Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol life Sci : CMLS. 2018;75(18):3313\u201327. https:\/\/doi.org\/10.1007\/s00018-018-2860-6.","journal-title":"Cell Mol life Sci : CMLS"},{"issue":"9","key":"2416_CR47","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1080\/15548627.2019.1591672","volume":"15","author":"BL Baechler","year":"2019","unstructured":"Baechler BL, Bloemberg D, Quadrilatero J. Mitophagy regulates mitochondrial network signaling, oxidative stress, and apoptosis during myoblast differentiation. Autophagy. 2019;15(9):1606\u201319. https:\/\/doi.org\/10.1080\/15548627.2019.1591672.","journal-title":"Autophagy"},{"key":"2416_CR48","doi-asserted-by":"publisher","unstructured":"Alexander CC, Munk\u00e1scy E, Tillmon H et al. HspB1 overexpression improves life span and Stress Resistance in an invertebrate model, the journals of gerontology. Series A, Biological sciences and medical sciences 77 (2) (2022) 268\u201375, https:\/\/doi.org\/10.1093\/gerona\/glab296","DOI":"10.1093\/gerona\/glab296"},{"issue":"2","key":"2416_CR49","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.apsb.2021.09.019","volume":"12","author":"D Du","year":"2022","unstructured":"Du D, Liu C, Qin M, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sinica B. 2022;12(2):558\u201380. https:\/\/doi.org\/10.1016\/j.apsb.2021.09.019.","journal-title":"Acta Pharm Sinica B"},{"issue":"12","key":"2416_CR50","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/s42255-023-00930-8","volume":"5","author":"A Picca","year":"2023","unstructured":"Picca A, Faitg J, Auwerx J, et al. Mitophagy in human health, ageing and disease. Nat Metabolism. 2023;5(12):2047\u201361. https:\/\/doi.org\/10.1038\/s42255-023-00930-8.","journal-title":"Nat Metabolism"},{"issue":"4","key":"2416_CR51","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/hep.26226","volume":"58","author":"K Begriche","year":"2013","unstructured":"Begriche K, Massart J, Robin MA, et al. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology (Baltimore MD). 2013;58(4):1497\u2013507. https:\/\/doi.org\/10.1002\/hep.26226.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"5","key":"2416_CR52","doi-asserted-by":"publisher","first-page":"8713","DOI":"10.3390\/ijms15058713","volume":"15","author":"F Nassir","year":"2014","unstructured":"Nassir F, Ibdah JA. Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15(5):8713\u201342. https:\/\/doi.org\/10.3390\/ijms15058713.","journal-title":"Int J Mol Sci"},{"key":"2416_CR53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41421-020-0141-7","volume":"6","author":"WW Yim","year":"2020","unstructured":"Yim WW, Mizushima N. Lysosome biology in autophagy. Cell Discovery. 2020;6:6. https:\/\/doi.org\/10.1038\/s41421-020-0141-7.","journal-title":"Cell Discovery"},{"issue":"3","key":"2416_CR54","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.7150\/ijbs.85443","volume":"20","author":"TM Chang","year":"2024","unstructured":"Chang TM, Chi MC, Chiang YC, et al. Promotion of ROS-mediated apoptosis, G2\/M arrest, and autophagy by naringenin in non-small cell lung cancer. Int J Biol Sci. 2024;20(3):1093\u2013109. https:\/\/doi.org\/10.7150\/ijbs.85443.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"2416_CR55","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1080\/15548627.2019.1635383","volume":"16","author":"XW Zhang","year":"2020","unstructured":"Zhang XW, Zhou JC, Peng D, et al. Disrupting the TRIB3-SQSTM1 interaction reduces liver fibrosis by restoring autophagy and suppressing exosome-mediated HSC activation. Autophagy. 2020;16(5):782\u201396. https:\/\/doi.org\/10.1080\/15548627.2019.1635383.","journal-title":"Autophagy"},{"issue":"9","key":"2416_CR56","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1080\/15548627.2023.2196876","volume":"19","author":"Y Li","year":"2023","unstructured":"Li Y, Xu J, Chen W, et al. Hepatocyte CD36 modulates UBQLN1-mediated proteasomal degradation of autophagic SNARE proteins contributing to septic liver injury. Autophagy. 2023;19(9):2504\u201319. https:\/\/doi.org\/10.1080\/15548627.2023.2196876.","journal-title":"Autophagy"},{"key":"2416_CR57","doi-asserted-by":"publisher","unstructured":"Chen Q, Kou H, Demy DL et al. The different roles of V-ATPase a subunits in phagocytosis\/endocytosis and autophagy, Autophagy (2024) 1\u201317, https:\/\/doi.org\/10.1080\/15548627.2024.2366748","DOI":"10.1080\/15548627.2024.2366748"},{"issue":"14","key":"2416_CR58","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1016\/j.molcel.2023.06.004","volume":"83","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zeng W, Han Y, et al. Lysosomal LAMP proteins regulate lysosomal pH by direct inhibition of the TMEM175 channel. Mol Cell. 2023;83(14):2524\u2013e25392527. https:\/\/doi.org\/10.1016\/j.molcel.2023.06.004.","journal-title":"Mol Cell"},{"issue":"1","key":"2416_CR59","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.1038\/s41467-022-33025-1","volume":"13","author":"W Zhang","year":"2022","unstructured":"Zhang W, Yang X, Li Y, et al. GCAF(TMEM251) regulates lysosome biogenesis by activating the mannose-6-phosphate pathway. Nat Commun. 2022;13(1):5351. https:\/\/doi.org\/10.1038\/s41467-022-33025-1.","journal-title":"Nat Commun"},{"issue":"2","key":"2416_CR60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","volume":"17","author":"SI Sayin","year":"2013","unstructured":"Sayin SI, Wahlstr\u00f6m A, Felin J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metabol. 2013;17(2):225\u201335. https:\/\/doi.org\/10.1016\/j.cmet.2013.01.003.","journal-title":"Cell Metabol"},{"issue":"9","key":"2416_CR61","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1080\/15548627.2023.2196876","volume":"19","author":"L Y","year":"2023","unstructured":"Y L. - hepatocyte CD36 modulates UBQLN1-mediated proteasomal degradation of autophagic. - Autophagy. 2023;19(9):2504\u201319. Epub (\u2013\u20091554\u20138635 (Electronic)) \u2013\u20092504\u20132519,.","journal-title":"- Autophagy"},{"issue":"1","key":"2416_CR62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","volume":"9","author":"JS Fleishman","year":"2024","unstructured":"Fleishman JS, Kumar S. Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets. Signal Transduct Target Therapy. 2024;9(1):97. https:\/\/doi.org\/10.1038\/s41392-024-01811-6.","journal-title":"Signal Transduct Target Therapy"},{"issue":"7922","key":"2416_CR63","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41586-022-05006-3","volume":"608","author":"JQ Wang","year":"2022","unstructured":"Wang JQ, Li LL, Hu A, et al. Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion. Nature. 2022;608(7922):413\u201320. https:\/\/doi.org\/10.1038\/s41586-022-05006-3.","journal-title":"Nature"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02416-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-024-02416-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02416-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T02:03:54Z","timestamp":1736474634000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-024-02416-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2416"],"URL":"https:\/\/doi.org\/10.1186\/s12944-024-02416-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5274949\/v1","asserted-by":"object"}]},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee of Guangzhou Jennio Biotechnology Co., Ltd. (Approval No. JENNIO-IACUC-2023-A066).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}